Company: SION
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0002036042-25-000016
Chunk: 207

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 207
---
,847)Net loss per share, basic and diluted$(0.62)$(3.84)Weighted-average common shares outstanding, basic and diluted26,596,059 3,082,635 Comprehensive loss:Net loss$(16,482)$(11,847)Unrealized loss on marketable securities(67)(8)Total other comprehensive loss(67)(8)Comprehensive loss$(16,549)$(11,855)

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-3

Table of Contents

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share amounts) 

(Unaudited)

Series SeedSeries ASeries BSeries C Common Stock AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncomeAccumulatedDeficitTotalStockholders’Equity (Deficit)Preferred Stock Preferred StockPreferred Stock Preferred Stock SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 4,722,763$5 $17,000 $368 $(181,086)$(163,713)Conversion of convertible preferred stock to common stock upon closing of initial public offering(3,963,963)(13,014)(5,704,161)(25,235)(11,370,621)(110,791)(18,628,970)(181,328)27,149,20627 330,340 — — 330,367 Issuance of common stock from initial public offering, net of issuance costs of $4,265—— —— —— —— 12,176,46712 199,558 — — 199,570 Vesting of restricted common stock awards—— —— —— —— 43,681— — — — — Stock-based compensation expense—— —— —— —— —— 2,094 — — 2,094 Unrealized loss on marketable securities—— —— —— —— —— — (67)— (67)Net loss—— —— —— —— —— —